ArticleMolecular therapy : the journal of the American Society of Gene Therapy2019
EZH2 Inhibition in Ewing Sarcoma Upregulates G
Abstract read
In one paragraph
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed.
- Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.Experimental hematology & oncology · 2026Review
- Model-dependent GD2 upregulation in Ewing sarcoma with the EZH2 inhibitor tazemetostat: Prerequisites for combination with GD2-specific CAR T cells.Research square · 2026Article
- Circumventing Ewing sarcoma tumor microenvironment resistance by IL1RAP CAR-modified TGFβ1-imprinted natural killer cells in combination with IL-15 agonist and anti-GD2 antibody.Journal for immunotherapy of cancer · 2026Article
- Epigenetic editing to advance CAR T cell therapy.Clinical epigenetics · 2026Review
- Decoding signaling architectures: CAR versus TCR dynamics in solid tumor immunotherapy.Acta biochimica et biophysica Sinica · 2026Review
- Article
- Precision epigenetic therapies in oncology.Cancer metastasis reviews · 2025Review
- EZH2-driven immune evasion at disease presentation defines a targetable high-risk subset of acute leukemia exemplified by t(16;21) FUS::ERG AML.bioRxiv : the preprint server for biology · 2025Article
- Article
- Enhancer zeste homolog 2 (EZH2) targeting by small interfering RNA (siRNA); recent advances and prospect.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- A novel therapeutic strategy for osteosarcoma using anti-GD2 ADC and EZH2 inhibitor.Biomarker research · 2025Article
- Dual Targeting EZH2 and Histone Deacetylases in Human Uterine Sarcoma Cells Under Both 2D and 3D Culture Conditions.Journal of cellular and molecular medicine · 2025Article
- Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy.Molecular cancer · 2025Review
- ZP4: A novel target for CAR-T cell therapy in triple negative breast cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy.Frontiers in immunology · 2025Review
- Developing CAR T-Cell Therapies for Pediatric Solid Tumors.Paediatric drugs · 2025Review
- CIMT 2024: Report on the 21st Annual Meeting of the Association for Cancer Immunotherapy.Human vaccines & immunotherapeutics · 2024Article
- Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells.Journal of hematology & oncology · 2024Article
- The efficacy and applicability of chimeric antigen receptor (CAR) T cell-based regimens for primary bone tumors: A comprehensive review of current evidence.Journal of bone oncology · 2024Review
- Combined use of niraparib enhanced the inhibitory effect of Anti-GD2 antibody on osteosarcoma cells.Discover oncology · 2024Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
20 authors.
Sareetha KailayangiriDepartment of Pediatric Hematology and Oncology, University Children's Hospital Münster, 48149 Münster, Germany.
Bianca AltvaterDepartment of Pediatric Hematology and Oncology, University Children's Hospital Münster, 48149 Münster, Germany.
Stefanie LeschDepartment of Pediatric Hematology and Oncology, University Children's Hospital Münster, 48149 Münster, Germany; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, 80539 Munich, Germany.
Sebastian BalbachDepartment of Pediatric Hematology and Oncology, University Children's Hospital Münster, 48149 Münster, Germany.
Claudia GöttlichTissue Engineering and Regenerative Medicine, University Hospital Würzburg, 97070 Würzburg, Germany; Fraunhofer Institute for Silicate Research (ISC), Translational Center Regenerative Therapies, 97082 Würzburg, Germany.
Johanna KühnemundtTissue Engineering and Regenerative Medicine, University Hospital Würzburg, 97070 Würzburg, Germany; Fraunhofer Institute for Silicate Research (ISC), Translational Center Regenerative Therapies, 97082 Würzburg, Germany.
Jan-Henrik MikeschDepartment of Medicine A, University Hospital Münster, 48149 Münster, Germany.
Sonja SchelhaasEuropean Institute for Molecular Imaging (EIMI), University of Münster, 48149 Münster, Germany.
Silke JamitzkyDepartment of Pediatric Hematology and Oncology, University Children's Hospital Münster, 48149 Münster, Germany.
Jutta MeltzerDepartment of Pediatric Hematology and Oncology, University Children's Hospital Münster, 48149 Münster, Germany.
Nicole FarwickDepartment of Pediatric Hematology and Oncology, University Children's Hospital Münster, 48149 Münster, Germany.
Lea GreuneDepartment of Pediatric Hematology and Oncology, University Children's Hospital Münster, 48149 Münster, Germany.
Maike FlueggeDepartment of Pediatric Hematology and Oncology, University Children's Hospital Münster, 48149 Münster, Germany.
Kornelius KerlDepartment of Pediatric Hematology and Oncology, University Children's Hospital Münster, 48149 Münster, Germany.
Holger N LodePediatric Hematology and Oncology, University Medicine Greifswald, 17475 Greifswald, Germany.
Nikolai SiebertPediatric Hematology and Oncology, University Medicine Greifswald, 17475 Greifswald, Germany.
Ingo MüllerDivision of Pediatric Stem Cell Transplantation and Immunology, Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Heike WallesTissue Engineering and Regenerative Medicine, University Hospital Würzburg, 97070 Würzburg, Germany; Fraunhofer Institute for Silicate Research (ISC), Translational Center Regenerative Therapies, 97082 Würzburg, Germany.
Wolfgang HartmannDivision of Translational Pathology, Gerhard-Domagk Institute for Pathology, University of Münster, 48149 Münster, Germany.
Claudia RossigDepartment of Pediatric Hematology and Oncology, University Children's Hospital Münster, 48149 Münster, Germany; Cells-in-Motion Cluster of Excellence (EXC 1003 - CiM), University of Münster, 48149 Münster, Germany. Electronic address: rossig@uni-muenster.de.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor (CAR) engineering of T cells allows one to specifically target tumor cells via cell surface antigens. A candidate target in Ewing sarcoma is the ganglioside G
Indexed as
Antigens, SurfaceBenzamidesBiphenyl CompoundsCell Line, TumorCell SurvivalEnhancer of Zeste Homolog 2 ProteinGangliosidesGene Expression Regulation, NeoplasticHumansImmunotherapyImmunotherapy, AdoptiveIndolesMorpholinesPromoter Regions, GeneticPyridonesReceptors, Chimeric AntigenAntigens, SurfaceBenzamidesBiphenyl CompoundsEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanganglioside, GD2GangliosidesGSK-2816126IndolesMorpholinesPyridonesReceptors, Chimeric Antigentazemetostatcellular immunotherapychimeric antigen receptorscombination therapyepigenetic agentsEwing sarcomagangliosides
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.